The Suboptimal Legibility of Prescribing Information in Pharmaceutical Advertisements

References

1. ↵
   Prescription Drug Advertising, 21 C.F.R. 202.1. (e) (1) (April 1, 2006) [cited 2007 Jan 10]. Available from: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=202.1.
2. ↵
   Lohiya S. The variable location, content and legibility of expiration dates on medicine containers. J Am Board Fam Pract 2004; 17: 395–397.

   OpenUrlCrossRefPubMed
3. ↵
   Glass L. Prevention. In: Glass L, editor. Occupational medicine practice guidelines. 2nd ed. Beverly Farms (MA): American College of Occupational and Environmental Medicine, OEM Press; 2004. p. 4.
4. ↵
   Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products. Final Rule, 21 C.F.R. Parts 201, 314, 601 (January 24, 2006) [cited 2007 Jan 10]. Available from: www.fda.gov/ohrms/dockets/98fr/06–545.pdf.
5. ↵
   Common Technical Document. Submitting Marketing Applications [cited 2007 Jan 19]. Available from: www.fda.gov/cder/guidance/4707dft.pdf.
6. ↵
   Villanueva P, Peiro S, Librero J. Accuracy of pharmaceutical advertisements in medical journals. Lancet 2003; 361: 27–32.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   Ma J, Stafford R, Cockburn I. A statistical analysis of the magnitude and composition of drug promotion in the US in 1998. Clinic Ther 2003; 25: 1503–1517.

   OpenUrl
8. ↵
   Monthly Prescribing Reference. New York (NY): BPA International. c2007 [cited 2007 Jan 10]. Available from: www.prescribingreference.com.